Candel Therapeutics, Inc. (CADL) stock
CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)
Close on Nov 17, 2026Market cap $413.20MP/E –Yield –
Candel Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Candel Therapeutics's operating margin for the twelve months ending Dec 31, 2022 was -27777.6%. For fiscal 2022 it was -27777.6%, against -20580.8% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -27777.6% | −7196.8 |
| FY2021 | Dec 31, 2021 | -20580.8% | −9532.8 |
| FY2020 | Dec 31, 2020 | -11048.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2022 | Dec 31, 2022 | -26132.3% | −1164.5 |
| Q3 FY2022 | Sep 30, 2022 | -28648.4% | −2748.4 |
| Q2 FY2022 | Jun 30, 2022 | -28235.5% | −11135.5 |
| Q1 FY2022 | Mar 31, 2022 | -28987.1% | −13964.5 |
| Q4 FY2021 | Dec 31, 2021 | -24967.7% | −5209.7 |
| Q3 FY2021 | Sep 30, 2021 | -25900.0% | −17032.3 |
| Q2 FY2021 | Jun 30, 2021 | -17100.0% | −8651.6 |
| Q1 FY2021 | Mar 31, 2021 | -15022.6% | – |
| Q4 FY2020 | Dec 31, 2020 | -19758.1% | – |
| Q3 FY2020 | Sep 30, 2020 | -8867.7% | – |
| Q2 FY2020 | Jun 30, 2020 | -8448.4% | – |
See a number that looks wrong?